Improved work productivity, safety, and quality of life with pegylated (40KDA) interferon alfa-2a (Pegasys™) therapy in the treatment of chronic hepatitis C.

被引：0
|
作者：
Perrillo, RP
Thuluvath, PJ
Rothstein, K
Alam, I
Palmer, M
Gordon, S
Pappas, SC
Wynohradnyk, L
机构：
[1] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA
[2] Johns Hopkins Hosp, Baltimore, MD 21287 USA
[3] Albert Einstein Med Ctr, Philadelphia, PA 19141 USA
[4] Clin Res Ctr, Austin, TX USA
[5] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[6] Roche Lab Inc, Nutley, NJ USA
来源：
HEPATOLOGY | 2000年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
809
引用
收藏
页码：362A / 362A
页数：1
相关论文
共 50 条
  • [31] Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
    Kim, Gun-Wook
    Jwa, Seung-Wook
    Song, Margaret
    Kim, Hoon-Soo
    Kim, Byung-Soo
    Kim, Moon-Bum
    Ko, Hyun-Chang
    ANNALS OF DERMATOLOGY, 2013, 25 (04) : 479 - 482
  • [32] Treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirin in hemophiliac patients
    Malekzadeh, R
    Merat, S
    Sohrabpour, AA
    Khaleghi, S
    Samimi-Rad, K
    GASTROENTEROLOGY, 2004, 126 (04) : A431 - A431
  • [33] Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy
    Zeuzem, S
    Heathcote, JE
    Martin, N
    Nieforth, K
    Modi, M
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (12) : 2201 - 2213
  • [34] Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients
    Gish, R
    Arora, S
    Nelson, D
    Fernandez, H
    Lamon, K
    JOURNAL OF HEPATOLOGY, 2004, 40 : 141 - 142
  • [35] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Kazuaki Nishio
    Takeshi Konndo
    Shunichi Okada
    Machiko Enchi
    World Journal of Hepatology, 2010, 2 (09) : 358 - 361
  • [36] Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C
    Nishio, Kazuaki
    Konndo, Takeshi
    Okada, Shunichi
    Enchi, Machiko
    WORLD JOURNAL OF HEPATOLOGY, 2010, 2 (09) : 358 - 361
  • [37] Treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin.
    Hassanein, TI
    Cooksley, G
    Sulkowski, M
    Smith, C
    Marinos, G
    Lai, MY
    Pastore, G
    Trejo-Estrada, R
    Vale, AHE
    Lok, AS
    Lin, A
    Green, J
    HEPATOLOGY, 2001, 34 (04) : 243A - 243A
  • [38] Enhanced virological response to treatment with 40 kDa peginterferon alfa-2a (PEGASYS®) in patients previously unresponsive to treatment with interferon alfa-2a.
    Minuk, GY
    Reddy, KR
    Lee, SS
    Heathcote, EJ
    O'Grady, J
    Pockros, PJ
    Shiffman, ML
    Naoumov, NV
    Sedarati, F
    Depamphilis, J
    HEPATOLOGY, 2001, 34 (04) : 330A - 330A
  • [39] Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C.
    Jensen, CDM
    Bernstein, DE
    Hassanein, TI
    Foster, GR
    Lee, SS
    Cheinquer, H
    Craxi, A
    Cooksley, WGE
    Klaskala, W
    Green, J
    HEPATOLOGY, 2002, 36 (04) : 603A - 603A
  • [40] Better safety and quality of life in patients with chronic hepatitis B than in patients with chronic hepatitis C when treated with peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy
    Marcellin, P
    Lau, G
    Piratvisuth, T
    Luo, KX
    Bonino, F
    Thongasawat, S
    Cooksley, G
    Hadziyannis, S
    Chutaputti, A
    Lu, ZM
    Fried, M
    Chow, WC
    Yurdaydin, C
    Berg, T
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 668A - 668A
12345